CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONJoan Bladé, David H. Vesole, Diana Samson et al.|British Journal of Haematology|1998Cited by 1.5k
Interleukin-1 beta-modulated gene expression in immortalized human chondrocytes.Mary B. Goldring, Jane F. Apperley|Journal of Clinical Investigation|1994Cited by 477
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinibAndreas Hochhaus, H. Kantarjian, Jeffrey H. Lipton et al.|Leukemia|2008Cited by 354
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow TransplantationMohamad Mohty, Rafael F. Duarte, Kai Hübel et al.|Bone Marrow Transplantation|2014Cited by 192
European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilizationKai Hübel, Rafael F. Duarte, M M Fresen et al.|Bone Marrow Transplantation|2011Cited by 65